Why Is Rhythm Pharma Stock Jumping Today?

Rhythm Pharmaceuticals (NASDAQ: RYTM) stock surged 5.47% after presenting six-month Phase 2 trial data for setmelanotide in Prader-Willi syndrome patients. The study showed meaningful improvements in BMI (3.06% mean reduction), body composition, hyperphagia, and behavioral measures, with a consistent safety profile. The trial enrolled 18 patients aged 6-23, with 17 remaining on active treatment.